Inscripta, Inc.

Benjamin Mijts

Juhan Kim

Aamir Mir

Andrew Garst

Kyle Seamon

Emily Feldman

Erik Zimmerman

The present disclosure provides a novel catalytically inactive MAD7 nuclease (dMAD7) that retains the ability to bind DNA in a sequence-specific manner. The MAD7 nuclease from which the dMAD7 has been derived was isolated from

Engineered enzyme

The present disclosure provides engineered nucleic acid-guided nickases and optimized scaffolds for making rational, direct edits to nucleic acids in live cells.

Nucleic acid-guided nickases

The present disclosure provides engineered RNA-guided enzymes for editing live cells.

Engineered enzymes

The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells; specifically, the present disclosure provides Type V MAD nucleases (e.g., RNA-guided nucleases or RGNs) with altered PAM preferences and/or altered activity at different temperatures or fidelity, and/or varied nuclease activities; all changes that may increase the versatility of a nucleic acid-guided nuclease for certain editing tasks.

Mad nucleases

The present disclosure provides new RNA-guided nuclease systems and engineered nickases for making rational, direct edits to nucleic acids in live cells.

The present disclosure provides new RNA-guided nucleases for making rational, direct edits to nucleic acids in live cells.

MAD nucleases

The present disclosure provides novel RNA-guided enzymes for making rational and direct edits to the genome of live cells.

Growing community of inventors

Boulder, CO, United States of America

Benjamin Mijts